CDC NEWS


powered by Surfing Waves


Latest News


Long COVID


09 Aug 2022

What Is Long COVID? Many people recover fully within a few days or weeks after being infected with SARS-CoV-2, the virus that causes COVID-19. But others have symptoms that linger for weeks, months, or even years after their initial diagnosis. Some people seem to recover from COVID-19 but then see their symptoms return, or they develop new symptoms within a few months. Even people who had no symptoms when they were infected can develop symptoms later. Either mild or severe COVID-19 can lead to long-lasting symptoms. Long COVID, long-haul COVID, post-COVID-19 condition, chronic COVID, and post-acute sequelae of SARS-CoV-2 (PASC) are all names for the health problems that some people experience within a few months of a COVID-19 diagnosis. Symptoms of long COVID may be the same or different than symptoms of COVID-19. Long COVID can also trigger other health conditions, such as diabetes or kidney disease.


Studying Long COVID Might Help Others With Post-Viral Fatigue Ailments


08 Aug 2022

For people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), “fatigue” doesn’t just mean being a little tired. It means a brain like molasses, a body exhausted and weak, and legs like jelly. If you are just tired, a typical remedy is to get some exercise or move around a bit to get blood flowing. But for people with ME/CFS, exercise does just the opposite. Physical or mental exertion can debilitate them, requiring recovery time that lasts for days, months, or years. Resting does not help. This symptom, known as post-exertional malaise, is one of the defining features of the disease, and it is poorly understood.


COVID-19 Boosters This Fall to Include Omicron Antigen, but Questions Remain About Its Value


11 Jul 2022

Probably many people who watched or participated in the June 28 virtual US Food and Drug Administration (FDA) advisory committee meeting about updating COVID-19 vaccines could agree on 1 point, made by the agency’s Peter Marks, MD, Ph.D: “It is science at its hardest.” More New Online Views 8,944 Citations 0 25 Medical News & Perspectives July 8, 2022 COVID-19 Boosters This Fall to Include Omicron Antigen, but Questions Remain About Its Value Rita Rubin, MA Article Information JAMA. Published online July 8, 2022. doi:10.1001/jama.2022.11252 related articles icon Related Articles Probably many people who watched or participated in the June 28 virtual US Food and Drug Administration (FDA) advisory committee meeting about updating COVID-19 vaccines could agree on 1 point, made by the agency’s Peter Marks, MD, PhD: “It is science at its hardest.” The SARS-CoV-2 Omicron variant is shown as green dots budding from a vero mammalian kidney epithelial cell 36 hours after infection. The SARS-CoV-2 Omicron variant is shown as green dots budding from a vero mammalian kidney epithelial cell 36 hours after infection. Steve Gschmeissner/sciencesource.com The FDA convened its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to discuss whether to add an Omicron component to boosters for the fall. In order to have enough doses by early October, “we will need to very rapidly move to let companies know what that selection will be,” Marks reminded the panelists. (How many doses will be enough isn’t clear—as of June 30, only 51.1% of fully vaccinated US adults aged 18 years or older had received 1 booster shot, while only 27% of fully vaccinated adults aged 50 years or older, for whom a second booster is recommended, had received 2, according to government data.)


COVID-19 Vaccines for Kids Under 5: What Parents Need To Know


19 Jun 2022

After multiple delays, very young children are finally eligible for COVID-19 vaccination. In mid-June, the Food and Drug Administration (FDA) granted emergency use authorization (EUA) to Pfizer’s COVID-19 vaccine for children ages 6 months to 5 years, as well as to Moderna's vaccine for kids ages 6 months to 6 years. The Centers for Disease Control and Prevention (CDC) soon after recommended the vaccines, which should become available early next week.


Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age


17 Jun 2022

Today, the U.S. Food and Drug Administration authorized emergency use of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 to include use in children down to 6 months of age. For the Moderna COVID-19 Vaccine, the FDA amended the emergency use authorization (EUA) to include use of the vaccine in individuals 6 months through 17 years of age. The vaccine had been authorized for use in adults 18 years of age and older. For the Pfizer-BioNTech COVID-19 Vaccine, the FDA amended the EUA to include use of the vaccine in individuals 6 months through 4 years of age. The vaccine had been authorized for use in individuals 5 years of age and older.




Articles


Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients


11 Aug 2021

In organ-transplant recipients, the standard two-dose vaccination strategy for coronavirus disease 2019 (Covid-19) has suboptimal immunogenicity.1 Both patients and health care providers have questioned whether a third-dose booster in transplant recipients would be safe and enhance immune response.2 We performed a double-blind, randomized, controlled trial of a third dose of mRNA-1273 vaccine (Moderna) as compared with placebo (the protocol is available with the full text of this letter at NEJM.org; ClinicalTrials.gov number, NCT04885907. opens in new tab).




Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents


15 Jul 2021

Children can experience SARS-CoV-2 postviral syndromes, but it is unclear to what extent these individuals are affected by long COVID. Evidence is predominantly limited to select populations without control groups,1-4 which does not allow estimating the overall prevalence and burden in a general pediatric population. We compared symptoms compatible with long COVID in children and adolescents (hereafter “children”) reported within 6 months after SARS-CoV-2 serologic testing.




Study Suggests Lasting Immunity After COVID-19, With a Big Boost From Vaccination


14 Jul 2021

After an infection with SARS-CoV-2, most people—even those with mild infections—appear to have some protection against the virus for at least a year, a recent follow-up study of recovered patients published in Nature suggests. What’s more, this and other research demonstrates that vaccinating these individuals substantially enhances their immune response and confers strong resistance against variants of concern, including the B.1.617.2 (delta) variant.




Return to Play After COVID-19 Infection in Children


28 Jun 2021

As the pandemic continues, children may experience long-term effects from COVID-19 infections. Because children may become “long haulers” or develop multisystem inflammatory syndrome in children (MIS-C), close monitoring after a COVID-19 diagnosis is important. In addition, children who are athletes require a separate return-to-play evaluation before they return to competitive sports or physical activities.




Association of Mask Mandates and COVID-19 Case Rates, Hospitalizations, and Deaths in Kansas


23 Jun 2021

This study examined the association between mask mandates in Kansas counties and COVID-19 cases, hospitalizations, and deaths. The Kansas executive order that took effect on July 3 was adopted by only 15 counties, and 68 counties did not have a mandate through October. A second mask mandate order took effect on November 25, and 40 additional counties adopted it.




Enroll for Free